Faculty

Institution

Unit

Venue

Apar Pataer

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Thoracic Surgery

The University of Texas MD Anderson Cancer Center

Apar Pataer is a Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on lung cancer and thoracic oncology, with particular emphasis on tumor biology, cancer immunotherapy, and radiation oncology. His recent work has uncovered mechanisms of tumor radioresistance, demonstrating that radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome resistance (Cancer Cell, 2025). He has also identified chromosomal 3q amplicon-encoded regulators of secretory vesicles that drive secretory addiction in cancer (Journal of Clinical Investigation, 2024) and explored how proteostasis network modulation confers resistance to oncogenic KRAS inhibitors (Science, 2023). His clinical investigations include neoadjuvant immunotherapy trials in resectable non-small cell lung cancer, notably the NEOSTAR platform trial (Nature Medicine, 2023), and integrative machine learning approaches to identify treatment-specific biomarkers.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Apar Pataer

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

lung cancer thoracic oncology oncology radiation oncology pathology cancer research cancer treatment cancer cells cell biology tumor biology oncogenes bronchial neoplasm neoadjuvant chemotherapy cancer immunotherapy cancer biology cancer care medicinal research pharmacology immunotherapy surgical oncology cell signaling cellular therapy respiratory medicine tumor targeting cancer immunosurveillance cancer growth cancer management therapeutic targets anti-cancer agents cell regulation prognosis cancer genetics prognostic biomarkers thoracic surgery cell death prognostic evaluation signaling pathways cancer imaging molecular cell biology cell transplantation apoptosis rna-dependent protein kinase neoadjuvant nivolumab histopathology photomedicine enzyme inhibition disease progression tumoral pathology drug targeting functional modification radiation effects radiation biology tumor suppressors therapeutic efficacy major pathological response surgical outcomes lung cancer patients major pathologic response neoadjuvant immunotherapy therapy resistance pharmaceutical sciences clinical evidence drug trials oncologic imaging computed tomography treatment and prevention viral oncology oncogenic agent pathological response surrogate endpoint neostar trial histopathologic response criteria resected lung cancer platform neostar trial image analysis approaches cell lung carcinomas

Notable Scholarly Works

Notable Federal Grants

Collaborators

Radiotherapy Promotes Cuproptosis and Synergizes With Cuproptosis Inducers to Overcome Tumor Radioresistance. Cancer Cell (2025)

cancer cellscancer researchoncologybrain tumor researchradiation oncologyradiation effectsradiation therapycuproptosis inducerstumor radioresistancetumor biologyradiation biologycell biology

1209Mo Neoadjuvant Nivolumab and Nivolumab+Ipilimumab in Resectable Non-Small Cell Lung Cancer: Combined Analysis of 5-Year Outcomes From Neostar and Ca209-159. Annals of Oncology (2024)

urologycancer immunotherapycancer treatmentmedicineneoadjuvant nivolumaboncologyradiation oncologysurgical oncologythoracic oncologyimmune checkpoint inhibitors5-year outcomescombined modality treatmentcancer carelung cancer

1242 Integrative Machine Learning for Identifying Treatment-Specific Impacts and Biomarkers Applied to Multi-Platform Data From Non-Small-Cell Lung Cancer Treated With Neoadjuvant Chemoimmunotherapies. Regular and Young Investigator Award Abstracts (2024)

Nathaniel DeboeverCheuk LeungYounghee LeeAditya MishraLorenzo FedericoAnnikka WeissferdtApar PataerHitoshi DejimaAlejandro Francisco-CruzFrank Rojas AlvarezLuisa M Solis SotoEdwin R ParraWilliam N WilliamAlexandre ReubenHumam KadaraIgnacio I WistubaJianjun ZhangStephen G SwisherAra A VaporciyanMarcelo V NegraoChantale BernatchezJia WuBissan Al-LazikaniDavid A JaffrayBoris SepesiNadim J AjamiJennifer A WargoPhillip FutrealHai TranJohn V HeymachHeather Y LinJ Jack LeeDon L GibbonsCara L HaymakerTina CasconeStephanie T Schmidt

treatment-specific impactsmachine learningbiomarkersmulti-platform dataneoadjuvant chemoimmunotherapiesnon-small-cell lung cancerlung cancer

Chromosomal 3Q Amplicon Encodes Essential Regulators of Secretory Vesicles That Drive Secretory Addiction in Cancer. Journal of Clinical Investigation (2024)

Xiaochao TanShike WangGuan-Yu XiaoChao WuXin LiuBiyao ZhouJiang YuDzifa Yawa DuoseYuanxin XiJing WangKunika GuptaApar PataerJack A RothMichael P KimFengju ChenChad J CreightonWilliam K RussellJonathan M Kurie

molecular cancergene expressioncancer cellsprotein secretionsecretory addictionbiochemistrymolecular biologyintracellular traffickingcancer geneticstumor biologycell signalingcell biologychromatinclinical investigationsecretory pathwaysecretory vesicles

Impact of Select Actionable Genomic Alterations on Efficacy of Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. Journal for ImmunoTherapy of Cancer (2024)

Nicolas ZhouCheuk H LeungWilliam N WilliamAnnikka WeissferdtApar PataerMyrna C B GodoyBrett W CarterFrank V FossellaAnne S TsaoGeorge R BlumenscheinXiuning LeJianjun ZhangFerdinandos SkoulidisJonathan M KurieMehmet AltanCharles LuBonnie S GlissonLauren A ByersYasir Y ElaminReza J MehranDavid C RiceGarrett L WalshWayne L HofstetterJack A RothHai T TranJia WuLuisa M Solis SotoHumam KadaraStephen G SwisherAra A VaporciyanDon L GibbonsHeather Y LinJ Jack LeeJohn V HeymachMarcelo V NegraoBoris SepesiTina Cascone

cancer immunotherapyneoadjuvant immunotherapytherapeutic efficacyimmunotherapyimmunologylung cancer

2334P Pathologic Patterns Following Different Neoadjuvant Therapies in Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology (2023)

pathologypathologic patternscancer treatmentbronchial neoplasmoncogenesoncologyradiation oncologytumor biologythoracic oncologydifferent neoadjuvant therapieslung cancer

Ep07.05-03 Neoadjuvant Chemotherapy or Chemo-Io in Resectable Kras-Mutated Non-Small Cell Lung Cancer (Nsclc) Patients: Single Center Experience. Journal of Thoracic Oncology (2023)

pathologycancer treatmentmedicinebronchial neoplasmoncogenesoncologyradiation oncologysurgical oncologysingle center experiencethoracic oncologyep07.05-03 neoadjuvant chemotherapylung cancer

Modulation of the Proteostasis Network Promotes Tumor Resistance to Oncogenic Kras Inhibitors. Science (2023)

Xiangdong LvXuan LuJin CaoQin LuoYao DingFanglue PengApar PataerDong LuDong HanEric MalmbergDoug W. ChanXiaoran WangSara R. SavageSufeng MaoJingjing YuFei PengLiang YanHuan MengLaure ManeixYumin HanYiwen ChenWantong YaoEric C. ChangAndre CaticXia LinGeorge MilesPengxiang HuangZheng SunBryan BurtHuamin WangJin WangQizhi Cathy YaoBing ZhangJack A. RothBert W. O’MalleyMatthew J. EllisMothaffar F. RimawiHaoqiang YingXi Chen

pathologydrug resistancecell regulationanti-cancer agentsfunctional modificationtumor biologypharmacologyoncogenic agentoncologycellular therapyremedial actioncancer immunotherapyoncogeneskras inhibitorsenzyme inhibitionleukemiasystems biologymedicinal researchtherapeutic targets

Neoadjuvant Chemotherapy Plus Nivolumab With or Without Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Platform Neostar Trial. Nature Medicine (2023)

Tina CasconeCheuk H. LeungAnnikka WeissferdtApar PataerBrett W. CarterMyrna C. B. GodoyHope FeldmanWilliam N. WilliamYuanxin XiSreyashi BasuJing Jing SunShalini S. YadavFrank R. Rojas AlvarezYounghee LeeAditya K. MishraLili ChenMonika PradhanHaiping GuoAnsam SinjabNicolas ZhouMarcelo V. NegraoXiuning LeCarl M. GayAnne S. TsaoLauren Averett ByersMehmet AltanBonnie S. GlissonFrank V. FossellaYasir Y. ElaminGeorge BlumenscheinJianjun ZhangFerdinandos SkoulidisJia WuReza J. MehranDavid C. RiceGarrett L. WalshWayne L. HofstetterRavi RajaramMara B. AntonoffJunya FujimotoLuisa M. SolisEdwin R. ParraCara HaymakerIgnacio I. WistubaStephen G. SwisherAra A. VaporciyanHeather Y. LinJing WangDon L. GibbonsJ. Jack LeeNadim J. AjamiJennifer A. WargoJames P. AllisonPadmanee SharmaHumam KadaraJohn V. HeymachBoris Sepesi

pharmacologyclinical trialscancer immunotherapycancer treatmentmedicinerespiratory medicineplatform neostar trialneoadjuvant chemotherapycancer researchoncologydrug trialsradiation oncologypharmacotherapyanti-cancer agentsthoracic oncologymedicinal researchclinical evidencelung cancer

Supplementary Figure From Distinct Immune Gene Programs Associated With Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable Nsclc. (2023)

cancer immunotherapypathologyoncogenestherapeutic vaccinesimmunomodulationsupplementary figureoncologyneoadjuvant chemotherapyhost tumor immunitycancer discoverycellular therapyimmunologyimmunotherapycancer immunosurveillance

1
2
3
4
5
6
7
10 / page

Apar Pataer

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Thoracic Surgery

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Apar Pataer

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Radiotherapy Promotes Cuproptosis and Synergizes With Cuproptosis Inducers to Overcome Tumor Radioresistance. Cancer Cell (2025)

cancer cellscancer researchoncologybrain tumor researchradiation oncologyradiation effectsradiation therapycuproptosis inducerstumor radioresistancetumor biologyradiation biologycell biology

1209Mo Neoadjuvant Nivolumab and Nivolumab+Ipilimumab in Resectable Non-Small Cell Lung Cancer: Combined Analysis of 5-Year Outcomes From Neostar and Ca209-159. Annals of Oncology (2024)

treatment-specific impactsmachine learningbiomarkersmulti-platform dataneoadjuvant chemoimmunotherapiesnon-small-cell lung cancerlung cancer

Chromosomal 3Q Amplicon Encodes Essential Regulators of Secretory Vesicles That Drive Secretory Addiction in Cancer. Journal of Clinical Investigation (2024)

Impact of Select Actionable Genomic Alterations on Efficacy of Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. Journal for ImmunoTherapy of Cancer (2024)

cancer immunotherapyneoadjuvant immunotherapytherapeutic efficacyimmunotherapyimmunologylung cancer

2334P Pathologic Patterns Following Different Neoadjuvant Therapies in Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology (2023)

pathologypathologic patternscancer treatmentbronchial neoplasmoncogenesoncologyradiation oncologytumor biologythoracic oncologydifferent neoadjuvant therapieslung cancer

Ep07.05-03 Neoadjuvant Chemotherapy or Chemo-Io in Resectable Kras-Mutated Non-Small Cell Lung Cancer (Nsclc) Patients: Single Center Experience. Journal of Thoracic Oncology (2023)

pathologycancer treatmentmedicinebronchial neoplasmoncogenesoncologyradiation oncologysurgical oncologysingle center experiencethoracic oncologyep07.05-03 neoadjuvant chemotherapylung cancer

Modulation of the Proteostasis Network Promotes Tumor Resistance to Oncogenic Kras Inhibitors. Science (2023)

Neoadjuvant Chemotherapy Plus Nivolumab With or Without Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Platform Neostar Trial. Nature Medicine (2023)

Supplementary Figure From Distinct Immune Gene Programs Associated With Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable Nsclc. (2023)

1
2
3
4
5
6
7
10 / page